CalciMedica CALC

NASDAQ CALC

$2.30 +0.28 (+13.61%)

At close: Sep 9, 2026 · 4:00 PM EDT

Key Stats

Market Cap7.90 Mn

P/E-0.38

P/S-9.36

Div. Yield0.00

Revenue Growth (1y) (Qtr)-160.58

Add ratio to table…

About

CalciMedica, Inc. is a clinical stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. The company’s product candidates target calcium release activated calcium (CRAC) channels. Its lead product candidate Auxora is an intravenous small molecule CRAC channel inhibitor containing the active compound zegocractin. CalciMedica is also advancing CM5480 a CRAC channel…

CalciMedica currently does not generate product revenue because it has not yet commercialized any therapeutic. The company finances its operations through public and private equity offerings and potential collaborations. Depending on financing it expects to continue research activities and clinical development.

CalciMedica competes in the biopharmaceutical sector with large multinational pharmaceutical companies established biotechnology firms specialty pharmaceutical companies and academic research institutions. Named competitors working on CRAC channel inhibitors include Rhizen Pharmaceuticals AG Vivreon Biosciences LLC Medshine Discovery Inc Eldec Pharmaceuticals and ChemiCare srl. The company believes its CRAC channel inhibitor platform offers a dual mechanism of action that modulates inflammatory signaling and protects tissue cells from calcium mediated injury. Its small molecule inhibitors act upstream of multiple inflammatory pathways providing rapid and reversible immunomodulation. The intravenous lipid nanoemulsion formulation of Auxora is designed to deliver drug to lipophilic organs such as the pancreas lungs and kidneys. These characteristics give CalciMedica a potential advantage over therapies that target single cytokines or require chronic dosing.

The company’s future customers are expected to be hospitals healthcare providers and patients suffering from acute inflammatory conditions such as acute pancreatitis acute kidney injury and pulmonary arterial hypertension.

Investment Thesis

▲ Bull case

CalciMedica's lead asset Auxora continues to demonstrate a favorable safety profile across multiple clinical indications despite the KOURAGE trial discontinuation, which is critical for long-term development potential. Management explicitly stated that no treatment-related safety concerns have been observed in over 350 critically ill patients treated with Auxora in completed trials, including the Phase 2b CARPO study in acute pancreatitis and the Phase 2 CARDEA trial in severe COVID-19 pneumonia. This consistent safety signal across diverse inflammatory conditions supports the mechanistic validity of CRAC channel inhibition and reduces a key binary risk for future trials. The absence of drug-related toxicity in the unblinded KOURAGE data further reinforces that the trial halt was due to enrichment or design issues rather than fundamental safety flaws, preserving Auxora's optionality in AKI and other indications. This robust safety foundation allows the company to refocus resources on higher probability-of-success programs like acute pancreatitis where efficacy signals are already established.
The company is advancing a dual-track strategy with Auxora in acute pancreatitis and CM5480 in pulmonary arterial hypertension, creating multiple near-term value inflection points that are underappreciated by the market. CalciMedica plans to finalize the design of a pivotal Auxora trial in acute pancreatitis by the first half of 2026 pending FDA feedback, with constructive engagement already noted in recent communications. Simultaneously, preclinical data for CM5480 published in JCI Insight and Human Immunology demonstrate effects on pulmonary vascular remodeling and right ventricular function, supporting its potential as a first-in-class oral therapy for PAH with IND submission expected in 2027. This diversification mitigates reliance on any single indication and leverages the core CRAC channel platform across distinct high-unmet-need markets. The parallel progression of both candidates increases the likelihood of at least one pivotal readout within the next 18-24 months, which could significantly derisk the investment thesis.
Recent financial results reveal an improving capital efficiency trajectory that extends the company's cash runway beyond current market expectations, providing critical time to execute clinical milestones. In Q1 2026, CalciMedica reported net income of $5.0 million driven by a $10.6 million increase in other income from fair value adjustments to financial instruments, alongside reduced R&D ($3.5M vs $4.2M YoY) and G&A ($2.1M vs $2.3M YoY) expenses. The company ended the quarter with $8.2 million in cash and expects this to fund operations into Q4 2026, which aligns with the anticipated timing for FDA feedback on the Auxora pivotal program in 2Q 2026 and IND-enabling work for CM5480. This financial flexibility reduces near-term dilution risk and allows management to pursue optimal trial designs without rushed compromises, particularly important given the lessons learned from the KOURAGE study redesign needs.

CalciMedica's lead asset Auxora continues to demonstrate a favorable safety profile across multiple clinical indications despite the KOURAGE trial discontinuation, which is critical for long-term development potential. Management explicitly stated that no treatment-related safety concerns have been observed in over 350 critically ill patients treated with Auxora in completed trials, including the Phase 2b CARPO study in acute pancreatitis and the Phase 2 CARDEA trial in severe COVID-19 pneumonia. This consistent safety signal across diverse inflammatory conditions supports the mechanistic validity of CRAC channel inhibition and reduces a key binary risk for future trials. The absence of drug-related toxicity in the unblinded KOURAGE data further reinforces that the trial halt was due to enrichment or design issues rather than fundamental safety flaws, preserving Auxora's optionality in AKI and other indications. This robust safety foundation allows the company to refocus resources on higher probability-of-success programs like acute pancreatitis where efficacy signals are already established.
The company is advancing a dual-track strategy with Auxora in acute pancreatitis and CM5480 in pulmonary arterial hypertension, creating multiple near-term value inflection points that are underappreciated by the market. CalciMedica plans to finalize the design of a pivotal Auxora trial in acute pancreatitis by the first half of 2026 pending FDA feedback, with constructive engagement already noted in recent communications. Simultaneously, preclinical data for CM5480 published in JCI Insight and Human Immunology demonstrate effects on pulmonary vascular remodeling and right ventricular function, supporting its potential as a first-in-class oral therapy for PAH with IND submission expected in 2027. This diversification mitigates reliance on any single indication and leverages the core CRAC channel platform across distinct high-unmet-need markets. The parallel progression of both candidates increases the likelihood of at least one pivotal readout within the next 18-24 months, which could significantly derisk the investment thesis.
Recent financial results reveal an improving capital efficiency trajectory that extends the company's cash runway beyond current market expectations, providing critical time to execute clinical milestones. In Q1 2026, CalciMedica reported net income of $5.0 million driven by a $10.6 million increase in other income from fair value adjustments to financial instruments, alongside reduced R&D ($3.5M vs $4.2M YoY) and G&A ($2.1M vs $2.3M YoY) expenses. The company ended the quarter with $8.2 million in cash and expects this to fund operations into Q4 2026, which aligns with the anticipated timing for FDA feedback on the Auxora pivotal program in 2Q 2026 and IND-enabling work for CM5480. This financial flexibility reduces near-term dilution risk and allows management to pursue optimal trial designs without rushed compromises, particularly important given the lessons learned from the KOURAGE study redesign needs.

▼ Bear case

The discontinuation of the KOURAGE trial in AKI/AHRF signals deeper challenges in patient population selection and trial execution that may recur in future studies, representing an underappreciated operational risk. Despite management's emphasis on no drug-related toxicity, the Independent Data Monitoring Committee's recommendation to reevaluate enrollment criteria suggests fundamental mismatches between the enrolled population and the drug's mechanism of action—potentially due to excessive disease severity, confounding comorbidities, or inadequate biomarker stratification. This is especially concerning given that AKI with AHRF is a high-mortality population where enrolling the right patients is extraordinarily difficult, and failure to do so could doom future trials regardless of drug efficacy. The company's plan to re-engage the FDA on future AKI development may face skepticism if the root cause of the KOURAGE failure is not fully addressed, particularly since no alternative path forward was detailed beyond generic design modifications.
CalciMedica's financial position remains fragile despite the Q1 2026 net income, which was largely driven by non-operational, non-recurring fair value adjustments rather than core business progress, creating a misleading impression of sustainability. The $10.6 million in other income stemmed from changes in the valuation of promissory notes and warrants—accounting artifacts unrelated to clinical or commercial advancement—while core R&D spending actually decreased year-over-year, potentially reflecting reduced trial activity rather than efficiency gains. With cash falling from $13.0 million at end-2025 to $8.2 million by Q1 2026 and no meaningful revenue on the horizon, the company's runway into Q4 2026 assumes no setbacks in FDA interactions or trial startups, which is optimistic given the complexity of designing a pivotal acute pancreatitis trial post-KOURAGE. Any delay in FDA feedback or need for additional preclinical work could force a dilutive financing well before expected milestones.
The preclinical progress of CM5480 in pulmonary arterial hypertension, while promising, faces significant translational hurdles and distant timelines that may not justify current investor optimism, representing a classic biotech overpromise risk. Although IND submission is anticipated in 2027, this timeline assumes successful completion of IND-enabling studies, which have not yet begun in earnest based on declining R&D expenses and limited recent updates beyond published literature. CM5480 must demonstrate not only target engagement but also a meaningful clinical advantage over existing PAH therapies in a notoriously difficult-to-treat population, where prior mechanistic approaches have failed despite strong preclinical rationale. The company's focus on this indication appears partly driven by the AKI setback, raising questions about strategic focus rather than pure opportunity, and the long timeline to human data increases the likelihood of capital depletion before proof of concept is achieved.

The discontinuation of the KOURAGE trial in AKI/AHRF signals deeper challenges in patient population selection and trial execution that may recur in future studies, representing an underappreciated operational risk. Despite management's emphasis on no drug-related toxicity, the Independent Data Monitoring Committee's recommendation to reevaluate enrollment criteria suggests fundamental mismatches between the enrolled population and the drug's mechanism of action—potentially due to excessive disease severity, confounding comorbidities, or inadequate biomarker stratification. This is especially concerning given that AKI with AHRF is a high-mortality population where enrolling the right patients is extraordinarily difficult, and failure to do so could doom future trials regardless of drug efficacy. The company's plan to re-engage the FDA on future AKI development may face skepticism if the root cause of the KOURAGE failure is not fully addressed, particularly since no alternative path forward was detailed beyond generic design modifications.
CalciMedica's financial position remains fragile despite the Q1 2026 net income, which was largely driven by non-operational, non-recurring fair value adjustments rather than core business progress, creating a misleading impression of sustainability. The $10.6 million in other income stemmed from changes in the valuation of promissory notes and warrants—accounting artifacts unrelated to clinical or commercial advancement—while core R&D spending actually decreased year-over-year, potentially reflecting reduced trial activity rather than efficiency gains. With cash falling from $13.0 million at end-2025 to $8.2 million by Q1 2026 and no meaningful revenue on the horizon, the company's runway into Q4 2026 assumes no setbacks in FDA interactions or trial startups, which is optimistic given the complexity of designing a pivotal acute pancreatitis trial post-KOURAGE. Any delay in FDA feedback or need for additional preclinical work could force a dilutive financing well before expected milestones.
The preclinical progress of CM5480 in pulmonary arterial hypertension, while promising, faces significant translational hurdles and distant timelines that may not justify current investor optimism, representing a classic biotech overpromise risk. Although IND submission is anticipated in 2027, this timeline assumes successful completion of IND-enabling studies, which have not yet begun in earnest based on declining R&D expenses and limited recent updates beyond published literature. CM5480 must demonstrate not only target engagement but also a meaningful clinical advantage over existing PAH therapies in a notoriously difficult-to-treat population, where prior mechanistic approaches have failed despite strong preclinical rationale. The company's focus on this indication appears partly driven by the AKI setback, raising questions about strategic focus rather than pure opportunity, and the long timeline to human data increases the likelihood of capital depletion before proof of concept is achieved.

Peer group

Peer Comparison

Companies in the Pharmaceuticals

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	JNJ	Johnson & Johnson	primary	643.26 Bn	30.58	6.57	60.73 Bn
2	ABBV	AbbVie Inc.	primary	443.31 Bn	70.19	6.89	70.82 Bn
3	MRK	Merck & Co., Inc.	primary	364.74 Bn	115.10	5.48	53.91 Bn
4	NVS	Novartis Ag	primary	266.46 Bn	9.25	3.88	9.59 Bn
5	PFE	Pfizer Inc	primary	158.57 Bn	36.30	2.49	63.19 Bn
6	SNY	Sanofi	primary	52.33 Bn	11.23	0.98	25.19 Bn
7	RVMD	Revolution Medicines, Inc.	primary	43.79 Bn	-24.76	-	-
8	INCY	Incyte Corp	primary	25.23 Bn	15.65	4.34	0.04 Bn

CalciMedica CALC

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password